The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Long-term results of a Phase Ib trial of Isa-VRd in newly diagnosed transplant-ineligible myeloma
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, presents the long-term follow-up data from a Phase Ib clinical trial (NCT02513186) investigating isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in patients with newly diagnosed multiple myeloma (MM) not eligible for or with no immediate intent for transplant. Dr Ocio highlights the encouraging efficacy of the treatment, with the majority of patients achieving a very good partial response (VGPR) or better and over 55% achieving measurable residual disease (MRD) negativity. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (Ai-generated)
Yes, we have now presented here at the last meeting the long-term follow-up of a clinical trial that was in fact the preliminary data that went for the IMROZ trial with isatuximab, lenalidomide, and dexamethasone (Isa-VRD) followed by lenalidomide and dexamethasone (Isa-RD) in patients non-transplant eligible. In this trial, we included 73 patients with a median age of 71...
Yes, we have now presented here at the last meeting the long-term follow-up of a clinical trial that was in fact the preliminary data that went for the IMROZ trial with isatuximab, lenalidomide, and dexamethasone (Isa-VRD) followed by lenalidomide and dexamethasone (Isa-RD) in patients non-transplant eligible. In this trial, we included 73 patients with a median age of 71. It’s important that we have two cohorts that are considered important. One is that we have 20% of patients that are over 75 years old, which I think is an elderly population. And also, we have some patients that could be candidates for transplant, that they didn’t have an immediate intent for transplantation.
The data in this quadruplet, as I said, the first time this quadruplet was carried out in this time in this population, is isatuximab-VRd was quite good, with 90, almost 100% of patients achieving a very good partial response (VGPR) or better, a very good response. And very interestingly, over 55% of them have MRD negativity. That is, and this also applies for the elderly patient population over 75 years old. And I think that’s also very good data.
In terms of progression-free survival (PFS), the majority of patients are doing fine. We have in the overall population, we have over 70% of patients alive and free of progression at five years, which is also, I think, good and in line, even a bit better as we said in the randomized trial, and this is also similar, maybe a bit lower for the 75 years or older patients with four years of progression-free survival.
In terms of safety, this could be a concern for this elderly population, but also the treatment was well=tolerated with, of course, infections that are well managed in this patient population with dose reduction and all the antibiotics and the preventive measures.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
